Recent Updates
Recently added Catalysts

TUB-030

Phase 1/2

Advanced Solid Tumors | Small Molecules | Oncology |Gilead Sciences, Inc.|Trials Updated: Sep 11, 2026

TUB-030 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Oct 2024

TUB-030 target and mechanism

Molecular target5T4
Target classAdc
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials1
Total Enrollment250

FDA Designations

No designations recorded

TUB-030 clinical trials

TUB-030 · 1 trial · 6 indications

Phase 1/2 1
NCT06657222First in Human Study of TUB-030 in Patients With Advanced Solid TumorsAdvanced Solid Tumors
RECRUITING250 Analytics
PHASE1/PHASE2RECRUITING
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Advanced Solid TumorsUnlock trial analytics

Study Endpoints

Primary Endpoints

Determination of MTD
From enrollment until 30 days after last study drug

The highest dose is defined at which no more than 1 of 3 patients have had a Dose Limiting Toxicity (DLT) according to NCI CTCAE V5.0 criteria

Secondary Endpoints

Number of patients with Adverse Events (AE)
From enrollment until 30 days after last study drug
Maximum concentration (Cmax)
From enrollment until 30 days after last study drug
Trough concentration (Cmin)
From enrollment until 30 days after last study drug
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1: dose escalationEXPERIMENTALDrug TUB-030, administered by intravenous (IV) infusion
Phase 2: dose optimization in NSCLC and HNSCCEXPERIMENTALDrug TUB-030, administered by intravenous (IV) infusion NSCLC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion HNSCC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion

Interventions

NameTypeDescription
TUB-030DRUGA complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: 1. Male or non-pregnant, non-breastfeeding female aged 18 years or older 2. Adequate organ function 3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had ...

Countries:United StatesCanadaFranceRomaniaSpain
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Advanced Solid Tumors")

Frequently asked questions about TUB-030

What is TUB-030?

TUB-030 is an investigational small molecule antibody-drug conjugate being developed by Gilead Sciences, Inc. for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved for any indication. The program is in oncology.

What is TUB-030 used for?

TUB-030 is being studied in adults with advanced solid tumors, including head and neck squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, and colorectal cancer. It is investigational and has not been approved for any use.

What does TUB-030 target?

TUB-030 targets 5T4, a tumor-associated antigen. It is an antibody-drug conjugate, meaning the targeting portion binds 5T4 and delivers a cytotoxic payload to cells expressing that target. This mechanism is designed to concentrate anti-tumor activity on 5T4-positive tumor cells.

Who is developing TUB-030?

TUB-030 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. Gilead is the sponsor of the clinical program evaluating the drug in advanced solid tumors.

What phase is TUB-030 in?

TUB-030 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program is currently recruiting participants.

What clinical trials is TUB-030 in?

TUB-030 is being evaluated in a first-in-human Phase 1 study, NCT06657222, titled a First in Human Study of TUB-030 in Patients With Advanced Solid Tumors. The trial is recruiting, has an enrollment of 250 participants, and is running in the United States, Canada, France, Romania, and Spain.